Modulators of phosphoinositide 3-kinase

Details Modulators of phosphoinositide 3-kinase Modulators of phosphoinositide 3-kinase

2005-06-21

2005-06-21

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S158000

Reexamination Certificate

active

06908932

ABSTRACT:
Compounds of formula 1 are effective modulators of PI3 kinase:wherein R1is H, hydroxy, amino, lower alkyl, or trihalomethyl;R2is amino, lower alkylamino, lower acylamino, arylamino, arylacyl-amino, heteroaryl-amino, heteroaryl-acyl amino, where aryl and heteroaryl are substituted with 0-3 substituents selected from the group consisting of halo, trihalomethyl, hydroxy, lower alkyl and lower alkoxy, or a substituent of the form —(CH2)n—C(═X)—R8, where n is 014 3 inclusive and X is O or NR9, where R9is H, lower alkyl, or R1and R2together form —CH═N—X— where X is CH, NH, O, or S, and R8is H, lower alkyl, lower alkoxy, aryl, aralkyl, or —(CH2)mCR10R11R12, where m is 0-3 inclusive, and R10, R11, and R12are each independently H, lower alkyl, aryl, aralkyl, hydroxy, lower alkoxy, aryloxy, aralkoxy, amino, lower alkyl-amino, arylamino, aralkylamino, heteroaryl amino, or heteroaralkyl amino, where aryl and heteroaryl are substituted with 0-3 substituents selected from the group consisting of halo, hydroxy, and lower alkyl;R3is H or lower alkyl; andR4, R5, R6, R7are each independently H, halo, hydroxy, amino, nitro, lower alkyl, or lower alkoxy;and pharmaceutically acceptable salts thereof.

REFERENCES:
patent: 5182290 (1993-01-01), Albaugh
patent: 5358949 (1994-10-01), Tabusa et al.
patent: 6429214 (2002-08-01), Zask et al.
patent: 6479512 (2002-11-01), Fraley et al.
Kappe, Chemical Abstracts 124:202096, abstract of Het Comm, vol. 1(5-6), pp 341-352, 1995.
Mohamed, Chemical Abstracts 121:133921, abstract of Indian J of Het Chem, vol. 3(2), pp 69-80, 1993.
Davies et al., “Specificity and mechanism of action of some commonly used protein kinase inhibitors,”Biochem. J351:95-105, 2000.
Franke et al., “P13K: downstream AKTion blocks apoptosis,”Cell88:435-437, 1997.
Haas-Kogan et al., “Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC,”Curr. Biol. 8:1195-1198, 1998.
Leibel et al., “Radiation therapy for neoplasms of the brain,”J. Neurosurg. 66:1-22, 1987.
Powis et al., “Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase,”Cancer Res. 54:2419-2423, 1994.
Shayesteh et al., “PIK3CA is implicated as an oncogene in ovarian cancer,”Nature Genetics21:99-102, 1999.
Vlahos et al., “A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phemyl-4H-1-benzopyran-4-one (LY294002),”J. Biol. Chem. 269:5241-5248, 1994.

Affiliated with

Also associated with

Rating

Modulators of phosphoinositide 3-kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulators of phosphoinositide 3-kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of phosphoinositide 3-kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3514600